Skip to main content
Signal8
Launch Terminal

Erasca, Inc. (ERAS)

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Erasca, Inc. logo

Erasca, Inc.

NASDAQ:ERASHealthcare
-4.21%$14.35
AH$14.20-1.05%vs close
Mkt Cap$5.02B
Float254.49M
O/S349.76M
Vol
$ Vol
RVOL
Inst Own81.2%
SI14.5%
Earnings
Dilution
Erasca, Inc. logoNASDAQ:ERAS$14.35-4.21%
Phase Distribution
9 lead-sponsored trials·4 active·4 completed
Phase 15
Phase 1/23
Phase 31
(2 more as collaborator)
Status Overview
Recruiting2
Active, not recruiting2
Completed4
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Active, not recruiting

    A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

    Naporafenib, Dacarbazine

    Advanced or Metastatic NRAS-mutant Melanoma

    Enrollment
    78
    Start
    Apr 2024
    Primary Completion
    Apr 2028est.
    Completion
    Dec 2028est.
    NCT06346067
  • Phase 1/2
    Completed

    A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

    ERAS-007, ERAS-601

    Advanced or Metastatic Solid Tumors

    Enrollment
    85
    Start
    May 2021
    Primary Completion
    Jul 2026
    Completion
    Jul 2026
    NCT04866134
  • Phase 1/2
    Completed

    A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

    ERAS-007, Encorafenib

    Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma

    Enrollment
    101
    Start
    Sep 2021
    Primary Completion
    Aug 2025
    Completion
    Jan 2026
    NCT05039177
  • Phase 1/2
    Withdrawn

    A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

    ERAS-007, ERAS-601

    Acute Myeloid Leukemia

    Enrollment
    0
    Start
    Mar 2022est.
    Primary Completion
    Mar 2025est.
    Completion
    Jun 2025est.
    NCT05279859
  • Phase 1
    Completed

    A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

    ERAS-601, Cetuximab

    Advanced or Metastatic Solid Tumors

    Enrollment
    90
    Start
    Dec 2020
    Primary Completion
    Feb 2026
    Completion
    Jun 2026
    NCT04670679
  • Phase 1
    Completed

    A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

    ERAS-007, ERAS-601

    Advanced Non-squamous Non-small-cell Lung Cancer

    Enrollment
    24
    Start
    Sep 2021
    Primary Completion
    Apr 2023
    Completion
    Apr 2023
    NCT04959981
  • Phase 1
    Active, not recruiting

    A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

    Naporafenib, Trametinib

    Advanced or Metastatic Solid Tumors

    Enrollment
    86
    Start
    Aug 2023
    Primary Completion
    Jul 2025
    Completion
    Dec 2026est.
    NCT05907304
  • Phase 1
    Recruiting

    A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    ERAS-0015, ERAS-0015 in combination

    Metastatic Solid Tumors

    Enrollment
    600
    Start
    Jun 2025
    Primary Completion
    May 2028est.
    Completion
    Dec 2028est.
    NCT06983743
  • Phase 1
    Recruiting

    A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

    ERAS-4001, ERAS-4001 in combination

    Metastatic Solid Tumors

    Enrollment
    200
    Start
    Aug 2025
    Primary Completion
    Aug 2028est.
    Completion
    Dec 2028est.
    NCT07021898
Search ClinicalTrials.gov for “Erasca”